{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-015390","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2024-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.894103+00:00","generated_at":"2026-06-03T16:46:29.177264+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Calidi Biotherapeutics closes $6.1M public offering of units with warrants; calls for reverse stock split vote","bullets":["Closed public offering of 15,197,500 units at $0.40 each for ~$6.1M gross proceeds; units include common stock (or pre-funded warrants) and several tranches of warrants.","Series A, B, and C warrants have exercise price of $0.60 per share; Series A, B-1, C-1 warrants expire in 5 yrs, Series B in 12 months, Series C in 4 months.","Proceeds will fund working capital, pre-clinical/clinical trials, and repayment of convertible promissory notes totaling $1.6M.","Stockholder meeting must be held by ~July 2, 2024 (75 days post-closing) to vote on reverse stock split; officers/directors agreed to vote in favor.","Ladenburg Thalmann acted as placement agent; fees include 8% cash fee, 1% management fee, and warrants for 5% of shares at $0.66 exercise price."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-015390","json":"https://secwatch.observer/filing/0001493152-24-015390.json","markdown":"https://secwatch.observer/filing/0001493152-24-015390.md","text":"https://secwatch.observer/filing/0001493152-24-015390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224015390/0001493152-24-015390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224015390/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T16:46:29.177264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"977abca20d3f1a82ab4709e13c7415d58bfb7372","claim":"Calidi Biotherapeutics, Inc. entered into Purchase Agreement with each purchaser identified on the signature pages thereto valued at aggregate gross proceeds of approximately $6.077 million (effective 2024-04-16).","evidence_excerpt":"On April 16, 2024, Calidi Biotherapeutics, Inc. (“we,” “our,” or the “Company”) agreed to sell in a public offering an aggregate of 13,232,500 Common Stock Units and 1,965,000 Pre-Funded Warrant Units (“PFW Units”) at an effective combined purchase price of $0.40 per Common Stock Unit or PFW Unit for aggregate gross proceeds of approximately $6.077 million before deducting placement agent fees and offering expenses payable by the Company (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224015390/0001493152-24-015390-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"each purchaser identified on the signature pages thereto"},{"label":"Value","value":"aggregate gross proceeds of approximately $6.077 million"},{"label":"Effective","value":"2024-04-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}